carboplatin,etoposide,atezolizumab,tiragolumab
roche
['skyscraper-02', 'lcsm,(-blcsm)', 'atezo', 'tiragolumab', 'sclc']
skyscraper-02: a phase iii, randomized, plcebo-controlled study of carbo-etoposide + atezo tiragolumab (anti-tigit) in pts w/ extensive stage sclc. allowed (un)treated asymptomatic brain mets--&gt; no difference in pfs &amp; os. #asco22 #lcsm 
Assistant Prof | Thoracic Oncology & Phase-I  @karmanoscancer | Previously @MayoCancerCare @gundersenhealth @JeffHealthAb @bpkihsofficial | Views/Tweets my own